Moderna will pay up to $2.25B to settle a patent lawsuit over lipid nanoparticle technology used in its COVID-19 vaccine.

Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.

MAHA brings chaos to biotech investment; Measles cases surge and threaten Trump vaccine policy changes; Autism scientists form independent group.

Each Thursday, we bring you updates on health policy, community surveys, new clinical studies, programs and services in Southwest and Southside Virginia. Got a tip or story idea? Email me at ...

Since the 1990s, the FDA has collected fees from drug companies to help pay for stepped-up staffing enable faster reviews of new prescription drugs and vaccines. In turn, the agency must meet certain ...

While the FDA appears to be adamant that uniQure conduct a sham surgery–controlled Phase 3 trial before AMT-130 can be ...

As we continue our celebration of Women's History Month, here are some life-changing inventions brought to us by Black women.

But just a week lat­er, on Feb. 18, the FDA back­tracked on its decision, saying that it will indeed review the vaccine, potentially in time for its approval for the ...

Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) ...

A lawmaker compared getting the vaccine with using meth. The Idaho Medical Association said his bill would infringe on ...

The FDA approved a vaccine for mumps nearly 60 years ago, so why are some areas of the United States experiencing outbreaks now, and who should be concerned?

Adults with prepandemic respiratory conditions, including asthma, bronchitis, and recurrent upper respiratory infections, are significantly more likely to develop long COVID after a mild-to-moderate ...